Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine/Paclitaxel/Carboplatin vs Paclitaxel/Carboplatin in 1st-line Ovarian Cancer
NCT00052468Phase 3Completed
- Sponsor
- AGO Study Group
- Start
- Aug 2002
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of gemcitabine in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC) (2 arms), sponsored by AGO Study Group. Primary endpoint: Overall Survival. Started Aug 2002; status: completed.
02
Drugs
gemcitabine
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00052468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00052468.